Triatomic Management’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Triatomic Management’s Portfolio STLN Stock Details STLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-802,965	Closed	-$369K	–	5
2024 Q2	$369K	Sell	802,965 -81,724	-9%	-$69.8K	10.89%	5
2024 Q1	$1.4M	Hold	884,689	–	–	2.61%	11
2023 Q4	$1.8M	Sell	884,689 -20,000	-2%	-$34.7K	2.3%	10
2023 Q3	$1.27M	Hold	904,689	–	–	0.88%	23
2023 Q2	$498K	Buy	904,689 +94,544	+12%	+$50K	0.51%	33
2023 Q1	$549K	Buy	810,145 +292,666	+57%	+$373K	0.37%	38
2022 Q4	$854K	Buy	517,479 +151,800	+42%	+$426K	0.72%	21
2022 Q3	$1.69M	Hold	365,679	–	–	0.97%	21
2022 Q2	$1.85M	Sell	365,679 -62,421	-15%	-$455K	1.7%	14
2022 Q1	$3.05M	Buy	428,100 +28,100	+7%	+$190K	2.48%	12
2021 Q4	$3.9M	Buy	+400,000	New	+$3.56M	2.39%	15

Other funds holding STLN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

TAS

TIFF Advisory Services Radnor, Pennsylvania $408M AUM 20.34% 1-Year Est. Return

Cincinnati Insurance Fairfield, Ohio $6.62B AUM 18.42% 1-Year Est. Return

KLP

Kent Lake PR Anasco, Puerto Rico $198M AUM 5.21% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

BFM

Boston Financial Management Boston, Massachusetts $3.31B AUM 19.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FCM

FourWorld Capital Management New York $196M AUM 42.39% 1-Year Est. Return

Triatomic Management's STLN Position: Q3 2024 in Review

Triatomic Management sold out of Starling Oncology Institute, Inc. Common Stock (STLN) in Q3 2024, closing a stake of 802,965 shares — an estimated $369K sold.

Triatomic Management first reported a position in STLN in Q4 2021 and held it in 11 quarters. The position peaked at $3.9M in Q4 2021. 34 funds tracked by Wall St. Rank hold STLN as of Q3 2024.

Triatomic Management reported no remaining Starling Oncology Institute, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
Triatomic Management sold 802,965 Starling Oncology Institute, Inc. Common Stock shares in Q3 2024, an estimated $369K.
Triatomic Management first reported a position in Starling Oncology Institute, Inc. Common Stock in Q4 2021 and held it in 11 quarters.
Triatomic Management's Starling Oncology Institute, Inc. Common Stock position peaked at $3.9M in Q4 2021.
34 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q3 2024.

Based on Triatomic Management's 13F filing for Q3 2024.